



PDR Network, LLC  
As the nation's leading distributor of drug labeling information, product safety alerts, and PEMS programs, PDR is committed to ensuring that prescribers have the right information at the point of prescribing. Our Network includes Physicians' Desk Reference®, the most highly trusted and commonly used drug information available in the U.S., PDR.net®, the online PDR mobile site, and the Health Care Modification Network (HCMN), the only specialized network for the electronic delivery of FDA-approved drug labeling and other healthcare information.

treatment regimens or patient populations that are included in approved labeling. The term "approved medical practice" includes the use that is included in approved drug labeling. In addition, the supplements listed in Section B are marketed under the Dietary Supplement Health and Education Act of 1994. Products marketed under the DSHEA do not require a premarket approval or approval from the FDA. The following disclaimer applies to all product information listed in this publication: This information is not intended to diagnose, treat,

# PHYSICIANS' DESK REFERENCE®

By improving communication and providing accurate information, FDA-approved Drug Alerts (DAs) and Drug Alerts (DAs) enhance patient safety and reduce medical liability. For more information on our electronic PDR® Drug Alerts, visit PDR.net.  
**About PDR**  
PDR is published by PDR Network, LLC in cooperation with certain U.S. Food and Drug Administration (FDA)-approved product labeling, in accordance with 21 CFR 314.101. PDR also includes prescribing information for products marketed without FDA approval. Information on some products

includes color-coded indices or blue pages at the front of the Reference Table to locate the brand names of products, as well as the PDR product you wish to review. As new data are added to the FDA-approved product labeling, you will receive the latest information to dress. As new data are added to the FDA-approved product labeling, you will receive the latest information to dress. As new data are added to the FDA-approved product labeling, you will receive the latest information to dress.

**CEO:** Edward Fotsch, MD  
**President:** David Tanzer  
**Chief Medical Officer:** Christine Côté, MD  
**Chief Technology Officer:** Nick Krym  
**Chief Financial Officer:** Dawn Carfora  
  
**Vice President, Product Management & Operations:** Valerie Berger  
**Vice President, Emerging Products:** Debra Del Guidice  
**Vice President, Corporate Development, Copy Sales & General Counsel:** Andrew Gelman  
**Vice President, Sales:** John Loucks  
**Vice President, Marketing:** Julie Baker  
**Vice President, Business Development:** Tom Dieker  
  
**Director of Sales:** Eileen Bruno  
**Business Manager:** Karen Fass  
**Senior Account Executives:** Marjorie A. Jaxel, Philip Molinaro  
**Account Executives:** Nick W. Clark, Carlos Comejo, Caryn Trick  
**Associate Account Executives:** Carol Levine, Janet Wallendal  
**Sales Coordinator:** Dawn McPartland  
  
**Senior Director, Operations & Client Services:** Stephanie Struble  
**Senior Director, Editorial & Publishing:** Bette Kennedy  
**Director, Clinical Services:** Sylvia Nashed, PharmD  
**Director, Marketing:** Kim Marich

**Senior Manager, Client Services:** Lisa Caporuscio  
**Manager, Clinical Services:** Nermin Kerolous, PharmD  
**Senior Drug Information Specialist, Database Management:** Christine Sunwoo, PharmD  
**Senior Drug Information Specialist, Product Development:** Anila Patel, PharmD  
**Drug Information Specialists:** Peter Leighton, PharmD; Kristine Mecca, PharmD; See-Won Seo, PharmD  
**Manager, Editorial Services:** Lori Murray  
**Associate Editor:** Jennifer Reed  
**Manager, Art Department:** Livio Udina  
**Electronic Publication Designer:** Carrie Spinelli Faeth  
  
**Director, PDR Production:** Jeffrey D. Schaefer  
**Associate Director, Manufacturing & Distribution:** Thomas Westburgh  
**Production Manager, PDR:** Steven Maher  
**Operations Database Manager:** Noel Deloughery  
**Senior Index Editor:** Allison O'Hare  
**Index Editor:** Julie L. Cross  
**Senior Production Coordinator:** Yasmin Hernández  
**Production Coordinators:** Eric Udina, Christopher Whalen  
**Format Editor:** Dan Cappello  
**Fulfillment Management Specialist:** Gary Lew  
**Manager, Customer Service:** Todd Taccetta

Copyright © 2010 PDR Network, LLC. Published by PDR Network, LLC at Montvale, NJ 07645-1725. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. Physicians' Desk Reference® and PDR® are registered trademarks of PDR Network, LLC. PDR® for Ophthalmic Medicines, PDR® for Nonprescription Drugs, Dietary Supplements, and Herbs; PDR® Pharmacopoeia; and PDR® Electronic Library are trademarks of PDR Network, LLC.

The FDA has also recognized that the FDCA Act does not, however, limit the manner in which a physician may use an approved drug. Once a product has been approved for marketing, a physician may choose to prescribe it for uses

- Liver problems
- High blood sugar
- Enlargement of benign tumors of the uterus ("fibroids")
- Mental depression

Some of the warning signs of these serious side effects include:

- Breast lumps
- Unusual vaginal bleeding
- Dizziness and faintness
- Changes in speech
- Severe headaches
- Chest pain
- Shortness of breath
- Pains in your legs
- Changes in vision
- Vomiting
- Yellowing of the skin, eyes or nail beds

Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptoms that concern you.

Less serious, but common side effects include:

- Headache
- Breast pain
- Irregular vaginal bleeding or spotting
- Stomach/abdominal cramps/bloating
- Nausea and vomiting
- Hair loss
- Fluid retention
- Vaginal yeast infection

These are not all the possible side effects of PREMPRO or PREMPHASE. For more information, ask your healthcare provider or pharmacist for advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What can I do to lower my chances of getting a serious side effect with PREMPRO or PREMPHASE?

- Talk with your healthcare provider regularly about whether you should continue taking PREMPRO or PREMPHASE
  - See your healthcare provider right away if you get vaginal bleeding while taking PREMPRO or PREMPHASE
  - Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else
  - If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.
  - If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease
- Ask your healthcare provider for ways to lower your chances of getting heart disease.

General information about the safe and effective use of PREMPRO and PREMPHASE

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take PREMPRO or PREMPHASE for conditions for which it was not prescribed. Do not give PREMPRO or PREMPHASE to other people, even if they have the same symptoms you have. It may harm them.

Keep PREMPRO and PREMPHASE out of the reach of children.

This leaflet provides a summary of the most important information about PREMPRO and PREMPHASE. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about PREMPRO and PREMPHASE that is written for health professionals by calling the toll free number 800-934-5556.

What are the ingredients in PREMPRO and PREMPHASE?

PREMPRO contains the same conjugated estrogens found in Premarin, which are a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17 $\alpha$ -dihydroequilin, 17 $\alpha$ -estradiol and 17 $\beta$ -dihydroequilin. PREMPRO also contains either 1.5, 2.5, or 5 mg of medroxyprogesterone acetate.

PREMPRO 0.3 mg/1.5 mg and 0.45 mg/1.5 mg tablets also contain calcium phosphate tribasic, microcrystalline cellulose, lactose monohydrate, hypromellose, magnesium stearate, polyethylene glycol, sucrose, hydroxypropyl cellulose, Eudragit NE 30D, povidone, titanium dioxide, yellow iron oxide, and black iron oxide.

PREMPRO 0.625 mg/2.5 mg and 0.625 mg/5 mg tablets also contain calcium phosphate tribasic, calcium sulfate, carnauba wax, cellulose, glyceryl monooleate, lactose, magnesium stearate, methylcellulose, pharmaceutical glaze, polyethylene glycol, sucrose, povidone, titanium dioxide, black iron oxide, and FD&C Blue No. 2 or red ferric oxide.

PREMPHASE is two separate tablets. One tablet (maroon color) is 0.625 mg of Premarin, which is a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17 $\alpha$ -dihydroequilin, 17 $\alpha$ -estradiol and 17 $\beta$ -dihydroequilin. The maroon tablet also contains calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magne-

sium stearate, polyethylene glycol, sucrose, titanium dioxide, FD&C Blue No. 2, FD&C Red No. 40. The second tablet (light-blue color) contains 0.625 mg of the same ingredients as the maroon color tablet plus 5 mg of medroxyprogesterone acetate. The light-blue tablet also contains calcium phosphate tribasic, calcium sulfate, carnauba wax, cellulose, glyceryl monooleate, lactose, magnesium stearate, methylcellulose, pharmaceutical glaze, polyethylene glycol, sucrose, povidone, titanium dioxide, FD&C Blue No. 2, and black iron oxide.

PREMPRO therapy consists of a single tablet to be taken once daily.

**PREMPRO 0.3 mg/1.5 mg**

Blister Card—Each carton includes 1 blister card containing 28 oval, cream tablets. Each tablet contains 0.3 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration.

**PREMPRO 0.45 mg/1.5 mg**

Blister Card—Each carton includes 1 blister card containing 28 oval, gold tablets. Each tablet contains 0.45 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration.

**PREMPRO 0.625 mg/2.5 mg**

EZ DIAL dispenser—Each carton includes 3 EZ DIAL® dispensers containing 28 tablets. One EZ DIAL dispenser contains 28 oval, peach tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 2.5 mg of medroxyprogesterone acetate for oral administration.

Blister Card—Each carton includes 1 blister card containing 28 oval, peach tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 2.5 mg of medroxyprogesterone acetate for oral administration.

**PREMPRO 0.625 mg/5 mg**

EZ DIAL dispenser—Each carton includes 3 EZ DIAL dispensers containing 28 tablets. One EZ DIAL dispenser contains 28 oval, light-blue tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.

Blister Card—Each carton includes 1 blister card containing 28 oval, light-blue tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.

PREMPHASE therapy consists of two separate tablets; one maroon Premarin tablet taken daily on days 1 through 14 and one light-blue tablet taken on days 15 through 28.

Each carton includes 1 blister pack containing 28 tablets. One blister pack contains 14 oval, maroon Premarin tablets containing 0.625 mg of conjugated estrogens and 14 oval, light-blue tablets that contain 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.

The appearance of PREMPRO tablets is a trademark of Wyeth Pharmaceuticals.

The appearance of PREMPHASE tablets is a trademark of Wyeth Pharmaceuticals. The appearance of the conjugated estrogens/medroxyprogesterone acetate combination tablets is a trademark.

Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].

United States Patent Number 5,547,948 (PREMPRO).

This product's label may have been updated. For current package insert and further product information, please visit [www.wyeth.com](http://www.wyeth.com) or call our medical communications department toll-free at 1-800-934-5556.

Wyeth®

Wyeth Pharmaceuticals Inc.

Philadelphia, PA 19101

W10537C006

ET01

Rev 02/10

Shown in Product Identification Guide, page 321

**PREVNAR® 13**

[pré'vár]

Pneumococcal 13-valent Conjugate Vaccine

[Diphtheria CRM<sub>197</sub> Protein]

Suspension for intramuscular injection

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PREVNAR 13 safely and effectively. See full prescribing information for PREVNAR 13.

PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM<sub>197</sub> Protein])

Suspension for intramuscular injection

Initial U.S. Approval: 2010

## INDICATIONS AND USAGE

Pevnar 13 is a vaccine approved for use in children 6 weeks through 5 years of age (prior to the 6<sup>th</sup> birthday).

Pevnar 13 is indicated for active immunization for the prevention of invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

Pevnar 13 is also indicated for the prevention of otitis media caused by *Streptococcus pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 6B, 7F, and 19A. (1)

## DOSAGE AND ADMINISTRATION

The four-dose immunization series consists of a 0.5 mL intramuscular injection administered at 2, 4, 6, and 12-15 months of age. (2.3)

## DOSAGE FORMS AND STRENGTHS

0.5 mL suspension for intramuscular injection, supplied in a single-dose pre-filled syringe. (3)

## CONTRAINDICATIONS

Severe allergic reaction (e.g., anaphylaxis) to any component of Pevnar 13, Pevnar (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM<sub>197</sub> Protein]) or any diphtheria toxoid-containing vaccine. (4)

## WARNINGS AND PRECAUTIONS

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including Pevnar 13, to infants born prematurely should be based on consideration of the individual infant's medical status, and the potential benefits and possible risks of vaccination. (5.4)

## ADVERSE REACTIONS

The most commonly reported solicited adverse reactions ( $\geq 20\%$ ) in U.S. clinical trials with Pevnar 13 were redness, swelling and tenderness at the injection site, fever, decreased appetite, irritability, increased sleep, and decreased sleep. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Wyeth Pharmaceuticals Inc. at 1-800-934-5556 or VAERS at 1-800-822-7967 or <http://vaers.hhs.gov>.

## DRUG INTERACTIONS

• Do not mix with any other vaccine in the same syringe. (7.1)

• Immunosuppressive therapies may reduce immune response to Pevnar 13. (7.2)

## USE IN SPECIFIC POPULATIONS

Safety and effectiveness of Pevnar 13 in children below the age of 6 weeks or on or after the 6<sup>th</sup> birthday have not been established. Pevnar 13 is not approved for use in children in these age groups. (8.4)

See 17 for PATIENT COUNSELING INFORMATION

Revised: 04/2010

## FULL PRESCRIBING INFORMATION: CONTENTS\*

- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
  - 2.1 Preparation for Administration
  - 2.2 Administration Information
  - 2.3 Vaccine Schedule for Infants and Toddlers
  - 2.4 Vaccine Schedule for Unvaccinated Children  $\geq 7$  Months of Age
  - 2.5 Pevnar 13 Vaccine Schedule for Children Previously Vaccinated With Pevnar (*Streptococcus pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F)
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 5 WARNINGS AND PRECAUTIONS
  - 5.1 Management of Allergic Reactions or Other Adverse Reactions
  - 5.2 Limitations of Vaccine Effectiveness
  - 5.3 Altered Immunocompetence
  - 5.4 Premature Infants
- 6 ADVERSE REACTIONS
  - 6.1 Clinical Trials Experience With Pevnar 13
  - 6.2 Clinical Trials Experience With Pevnar
  - 6.3 Post-marketing Experience With Pevnar
- 7 DRUG INTERACTIONS
  - 7.1 Concomitant Immunizations
  - 7.2 Immunosuppressive Therapies
- 8 USE IN SPECIFIC POPULATIONS
  - 8.1 Pregnancy
  - 8.4 Pediatric Use
  - 8.5 Geriatric Use
- 10 OVERDOSAGE
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
  - 12.1 Mechanism of Action
- 13 NONCLINICAL TOXICOLOGY
  - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES
  - 14.1 Pevnar Efficacy Data
  - 14.2 Evaluation of Pevnar 13 Effectiveness
- 16 HOW SUPPLIED/STORAGE AND HANDLING

## 17 PATIENT COUNSELING INFORMATION

## 17.1 Potential Benefits and Risks

## 17.2 Adverse Reactions

\* Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

## 1 INDICATIONS AND USAGE

Prevnar 13™ is a vaccine approved for use in children 6 weeks through 5 years of age (prior to the 6<sup>th</sup> birthday). Pevnar 13 is indicated for active immunization for the prevention of invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

Pevnar 13 is also indicated for the prevention of otitis media caused by *Streptococcus pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A.

## 2 DOSAGE AND ADMINISTRATION

For intramuscular injection only.

## 2.1 Preparation for Administration

Since this product is a suspension containing an adjuvant, shake vigorously immediately prior to use to obtain a homogeneous, white suspension in the vaccine container. Do not use the vaccine, if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration [see Description (11)]. This product should not be used if particulate matter or discoloration is found.

Do not mix Pevnar 13 with other vaccines/products in the same syringe.

## 2.2 Administration Information

Do not inject intravenously, intradermally, or subcutaneously.

Each 0.5 mL dose is to be injected intramuscularly. The preferred sites for injection are the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in toddlers and young children. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.

## 2.3 Vaccine Schedule for Infants and Toddlers

Pevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12-15 months of age.

Table 1: Vaccination Schedule for Infants and Toddlers

Dose	Dose 1 <sup>†</sup>	Dose 2 <sup>†</sup>	Dose 3 <sup>†</sup>	Dose 4 <sup>‡</sup>
Age at Dose	2 months	4 months	6 months	12-15 months

\* Dose 1 may be given as early as 6 weeks of age.

† The recommended dosing interval is 4 to 8 weeks.

‡ The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.

## 2.4 Vaccine Schedule for Unvaccinated Children ≥7 Months of Age

For children who are beyond the age of the routine infant schedule and have not received Pevnar or Pevnar 13, the following catch-up schedule applies:

Table 2: Vaccine Schedule for Unvaccinated Children ≥7 Months of Age

Age at First Dose	Total Number of 0.5 mL Doses
7-11 months of age	3*
12-23 months of age	2 <sup>†</sup>
24 months through 5 years of age (prior to the 6 <sup>th</sup> birthday)	1

\* The first 2 doses at least 4 weeks apart; third dose after the one-year birthday, separated from the second dose by at least 2 months.

† Two doses at least 2 months apart.

The immune responses induced by this catch-up schedule may result in lower antibody concentrations for some serotypes, compared to antibody concentrations following 4 doses of Pevnar 13 (given at 2, 4, 6, and 12 to 15 months). In children 24 months through 5 years of age, the catch-up schedule may result in lower antibody concentrations for some serotypes, compared to antibody concentrations following 3 doses of Pevnar 13 (given at 2, 4, and 6 months). The clinical relevance of these lower antibody responses is not known.

Table 3: Percentage of U.S. Infant and Toddler Subjects Reporting Solicited Local Reactions at the Pevnar 13 or Pevnar Injection Sites Within 7 Days After Each Vaccination at 2, 4, 6, and 12-15 Months of Age<sup>a</sup>

Graded Local Reaction	Dose 1		Dose 2		Dose 3		Dose 4	
	Pevnar 13 (N <sup>b</sup> =1375-1612)	Pevnar (N <sup>b</sup> =516-606)	Pevnar 13 (N <sup>b</sup> =1069-1331)	Pevnar (N <sup>b</sup> =405-510)	Pevnar 13 (N <sup>b</sup> =998-1206)	Pevnar (N <sup>b</sup> =348-446)	Pevnar 13 (N <sup>b</sup> =874-1060)	Pevnar (N <sup>b</sup> =283-379)
<b>Redness<sup>c</sup></b>								
Any	24.3	26.0	33.3	29.7	37.1	36.6	42.3	45.5
Mild	23.1	25.2	31.9	28.7	35.3	35.3	39.5	42.7
Moderate	2.2	1.5	2.7	2.2	4.6	5.1	9.6	13.4*
Severe	0	0	0	0	0	0	0	0
<b>Swelling<sup>c</sup></b>								
Any	20.1	20.7	25.2	22.5	26.8	28.4	31.6	36.0*
Mild	17.2	18.7	23.8	20.5	25.2	27.5	29.4	33.8
Moderate	4.9	3.9	3.7	4.9	3.8	5.8	8.3	11.2*
Severe	0	0	0.1	0	0	0	0	0
<b>Tenderness</b>								
Any	62.5	64.5	64.7	62.9	59.2	60.8	57.8	62.5
Interferes with limb movement	10.4	9.6	9.0	10.5	8.4	9.0	6.9	5.7

\* Statistically significant difference  $p < 0.05$

<sup>a</sup> Data are from three primary U.S. safety studies (the U.S. phase II infant study, the pivotal U.S. non-inferiority study, and the U.S. consistency study). All infants received concomitant routine infant immunizations. Concomitant vaccines and pneumococcal conjugate vaccines were administered in different limbs.

<sup>b</sup> Number of subjects reporting Yes for at least 1 day or No for all days.

<sup>c</sup> Diameters were measured in caliper units of whole numbers from 1 to 14 or 14+. One caliper unit = 0.5 cm. Measurements were rounded up to the nearest whole number. Intensity of induration and erythema were then characterized as Mild (0.5-2.0 cm), Moderate (2.5-7.0 cm), or Severe (>7.0 cm).

2.5 Pevnar 13 Vaccine Schedule for Children Previously Vaccinated With Pevnar (*Streptococcus pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F)

Children who have received one or more doses of Pevnar may complete the 4-dose immunization series with Pevnar 13. Children 15 months through 5 years of age who have received 4 doses of Pevnar may receive one dose of Pevnar 13 to elicit immune responses to the six additional serotypes. This catch-up dose of Pevnar 13 should be administered with an interval of at least 8 weeks after the fourth dose of Pevnar. The immune responses induced by this Pevnar 13 transition schedule may result in lower antibody concentrations for the 6 additional serotypes (types 1, 3, 5, 6A, 7F, and 19A), compared to antibody concentrations following 4 doses of Pevnar 13 (given at 2, 4, 6, and 12 to 15 months). The clinical relevance of these lower antibody responses is not known.

## 3 DOSAGE FORMS AND STRENGTHS

Pevnar 13 is a suspension for intramuscular injection available in 0.5 mL single-dose pre-filled syringes.

## 4 CONTRAINDICATIONS

Severe allergic reaction (e.g., anaphylaxis) to any component of Pevnar 13, Pevnar or any diphtheria toxoid-containing vaccine.

## 5 WARNINGS AND PRECAUTIONS

## 5.1 Management of Allergic Reactions or Other Adverse Reactions

Before administration of any dose, all precautions should be taken to prevent allergic or any other adverse reactions. This includes a review of the patient's immunization history for possible sensitivity to the vaccine or similar vaccines and for previous vaccination-related adverse reactions in order to determine the existence of any contraindication to immunization with Pevnar 13 and to allow an assessment of risks and benefits. Epinephrine and other appropriate agents used for the control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur following the administration of the vaccine.

## 5.2 Limitations of Vaccine Effectiveness

Pevnar 13 may not protect all individuals receiving the vaccine. Pevnar 13 will not protect against *Streptococcus pneumoniae* serotypes that are not in the vaccine or serotypes unrelated to those in the vaccine. It will also not protect against other microorganisms. This vaccine does not treat active infection.

Protection against otitis media is expected to be substantially lower than protection against invasive disease. In addition, because otitis media is caused by many organisms other than the 7 serotypes of *Streptococcus pneumoniae* included in the indication, protection against all causes of otitis media is expected to be lower than for pneumococcal otitis media caused by these 7 vaccine serotypes [see Clinical Studies (14.2)].

The duration of protection from immunization is not known.

## 5.3 Altered Immunocompetence

Data on the safety and effectiveness of Pevnar 13 when administered to children in specific groups at higher risk for invasive pneumococcal disease (e.g., children with congenital or acquired splenic dysfunction, HIV infection, malignancy, nephrotic syndrome) are not available.

Children in these groups may have reduced antibody response to active immunization due to impaired immune responsiveness. Vaccination in high-risk groups should be considered on an individual basis [see Drug Interactions (7.2)].

The use of pneumococcal conjugate vaccine does not replace the use of 23-valent pneumococcal polysaccharide vaccine (PPV23) in children ≥24 months of age with sickle cell disease, asplenia, HIV infection, chronic illness or who are otherwise immunocompromised.

## 5.4 Premature Infants

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including Pevnar 13, to infants born prematurely should be based on consideration of the individual infant's medical status, and the potential benefits and possible risks of vaccination.

## 6 ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse-reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. As with any vaccine, there is the possibility that broad use of Pevnar 13 could reveal adverse reactions not observed in clinical trials.

## 6.1 Clinical Trials Experience With Pevnar 13

The safety of Pevnar 13 was evaluated in 13 clinical trials in which 4,729 infants and toddlers received at least one dose of Pevnar 13 and 2,760 infants and toddlers received at least one dose of Pevnar active control. Safety data for

IMPORTANT NOTICE: Updated drug information is sent bi-monthly via the PDR® Update Insert. For monthly email updates, register at PDR.net.

the first three doses are available for all 13 infant studies; dose 4 data are available for 10 studies; and data for the 6-month follow-up are available for 7 studies. The vaccination schedule and concomitant vaccinations used in these infant trials were consistent with country-specific recommendations and local clinical practice. There were no substantive differences in demographic characteristics between the vaccine groups. By race, 84.0% of subjects were White, 6.0% were Black or African-American, 5.8% were Asian and 3.8% were of 'Other' race (most of these being biracial). Overall, 52.3% of subjects were male infants.

Three studies in the U.S. evaluated the safety of Prevnar 13 when administered concomitantly with routine U.S. pediatric vaccinations at 2, 4, 6, and 12-15 months of age. Solicited local and systemic adverse events were recorded daily by parents/guardians using an electronic diary for 7 consecutive days following each vaccination. For unsolicited adverse events, study subjects were monitored from administration of the first dose until one month after the infant series, and for one month after the administration of the toddler dose. Information regarding unsolicited and serious adverse events, newly diagnosed chronic medical conditions, and hospitalizations since the last visit were collected during the clinic visit for the fourth-study dose and during a scripted telephone interview 6 months after the fourth-study dose. Serious adverse events were also collected throughout the study period. Overall, the safety data show a similar proportion of Prevnar 13 and Prevnar recipients reporting serious adverse events. Among U.S. study subjects, a similar proportion of Prevnar 13 and Prevnar recipients reported solicited local and systemic adverse reactions as well as unsolicited adverse events.

#### Serious Adverse Events in All Infant and Toddler Clinical Studies

Serious adverse events were collected throughout the study period for all 13 clinical trials. This reporting period is longer than the 30-day post-vaccination period used in some vaccine trials. The longer reporting may have resulted in serious adverse events being reported in a higher percentage of subjects than for other vaccines. Serious adverse events reported following vaccination in infants and toddlers occurred in 8.2% among Prevnar 13 recipients and 7.2% among Prevnar recipients. Serious adverse events observed during different study periods for Prevnar 13 and Prevnar respectively were: 1) 3.7% and 3.5% from dose 1 to the bleed after the infant series; 2) 3.6% and 2.7% from the bleed after the infant series to the toddler dose; 3) 0.9% and 0.8% from the toddler dose to the bleed after the toddler dose and 4) 2.5% and 2.8% during the 6 month follow up period after the last dose.

The most commonly reported serious adverse events were in the 'Infections and infestations' system organ class including bronchiolitis (0.9%, 1.1%), gastroenteritis, (0.9%, 0.9%), and pneumonia (0.9%, 0.5%) for Prevnar 13 and Prevnar respectively.

There were 3 (0.063%) deaths among Prevnar 13 recipients, and 1 (0.036%) death in Prevnar recipients, all as a result of sudden infant death syndrome (SIDS). These SIDS rates are consistent with published age specific background rates of SIDS from the year 2000.

There was 1 hypotonic-hyporesponsive episode adverse reaction reported (0.015%).

#### Solicited Adverse Reactions in the Three U.S. Infant and Toddler Studies

A total of 1,907 subjects received at least 1 dose of Prevnar 13 and 701 subjects received at least 1 dose of Prevnar in the three U.S. studies. Most subjects were White (77.3%), 14.2% were Black or African-American, and 1.7% were Asian; 79.1% of subjects were non-Hispanic and non-Latino and 14.6% were Hispanic or Latino. Overall, 53.6% of subjects were male infants.

The incidence and severity of solicited adverse reactions that occurred within 7 days following each dose of Prevnar 13 or Prevnar administered to U.S. infants and toddlers are shown in Tables 3 and 4.

[See table 3 at top of previous page]

[See table 4 above]

#### Unsolicited Adverse Reactions in the Three U.S. Infant and Toddler Safety Studies

The following were determined to be adverse drug reactions based on experience with Prevnar 13 in clinical trials: Reactions occurring in greater than 1% of infants and toddlers: diarrhea, vomiting, and rash.

Reactions occurring in less than 1% of infants and toddlers: crying, hypersensitivity reaction (including face edema, dyspnea, and bronchospasm), seizures (including febrile seizures), and urticaria or urticaria-like rash.

#### Safety Assessments in the Catch-Up Studies

In a catch-up study conducted in Poland, 354 children (7 months through 5 years of age) receiving at least one dose of Prevnar 13 were also monitored for safety. All subjects in this study were White and non-Hispanic. Overall, 49.6% of subjects were male infants. The incidence and severity of solicited adverse reactions that occurred within 4 days fol-

Table 4: Percentage of U.S. Infant and Toddler Subjects Reporting Solicited Systemic Adverse Reactions Within 7 Days After Each Vaccination at 2, 4, 6, and 12-15 Months of Age<sup>a,b</sup>

Graded Systemic Events	Dose 1		Dose 2		Dose 3		Dose 4	
	Prevnar 13 (N <sup>a</sup> =1360-1707)	Prevnar (N <sup>a</sup> =497-640)	Prevnar 13 (N <sup>a</sup> =1084-1469)	Prevnar (N <sup>a</sup> =409-555)	Prevnar 13 (N <sup>a</sup> =997-1361)	Prevnar (N <sup>a</sup> =354-521)	Prevnar 13 (N <sup>a</sup> =850-1227)	Prevnar (N <sup>a</sup> =278-436)
Fever <sup>c</sup>								
Any	24.3	22.1	36.5	32.8	30.3	31.6	31.9	30.6
Mild	23.6	21.7	34.9	31.6	29.1	30.2	30.3	30.0
Moderate	1.1	0.6	3.4	2.8	4.2	3.3	4.4	4.6
Severe	0.1	0.2	0.1	0.3	0.1	0.7	1.0	0
Decreased appetite	48.3	43.6	47.8	43.6	47.6	47.6	51.0	49.4
Irritability	85.6	83.6	84.8	80.4	79.8	80.8	80.4	77.8
Increased sleep	71.5	71.5	66.6	63.4	57.7	55.2	48.7	55.1
Decreased sleep	42.5	40.6	45.6	43.7	46.5	47.7	45.3	40.3

<sup>a</sup> Number of subjects reporting Yes for at least 1 day or No for all days.

<sup>b</sup> Data are from three primary U.S. safety studies (the U.S. phase II infant study, the pivotal U.S. non-inferiority study, and the U.S. consistency study). All infants received concomitant routine infant immunizations. Concomitant vaccines and pneumococcal conjugate vaccines were administered in different limbs.

<sup>c</sup> Fever gradings: Mild ( $\geq 38^{\circ}\text{C}$  but  $\leq 39^{\circ}\text{C}$ ), Moderate ( $> 39^{\circ}\text{C}$  but  $\leq 40^{\circ}\text{C}$ ), and Severe ( $> 40^{\circ}\text{C}$ ). No other systemic event other than fever was graded. Parents reported the use of antipyretic medication to treat or prevent symptoms in 62 to 75% of subjects after any of the 4 doses. There were no statistical differences between the Prevnar 13 and Prevnar groups.

Table 5: Percentage of Subjects 7 Months Through 5 Years of Age Reporting Solicited Local Reactions Within 4 Days After Each Catch-Up Prevnar 13 Vaccination<sup>a</sup>

Graded Local Reaction	7 through 11 months			12 through 23 months		24 months through 5 years
	Dose 1 (N <sup>b</sup> =86 %)	Dose 2 (N <sup>b</sup> =86-87 %)	Dose 3 (N <sup>b</sup> =78-82 %)	Dose 1 (N <sup>b</sup> =108-110 %)	Dose 2 (N <sup>b</sup> =98-106 %)	Dose 1 (N <sup>b</sup> =147-149 %)
Redness <sup>c</sup>						
Any	48.8	46.0	37.8	70.0	54.7	50.0
Mild	41.9	40.2	31.3	55.5	44.7	37.4
Moderate	16.3	9.3	12.5	38.2	25.5	25.7
Severe	0.0	0.0	0.0	0.0	0.0	0.0
Swelling <sup>c</sup>						
Any	36.0	32.2	25.0	44.5	41.0	36.9
Mild	32.6	28.7	20.5	36.7	36.2	28.2
Moderate	11.6	14.0	11.3	24.8	12.1	20.3
Severe	0.0	0.0	0.0	0.0	0.0	0.0
Tenderness						
Any	15.1	15.1	15.2	33.3	43.7	42.3
Interferes with limb movement	1.2	3.5	6.4	0.0	4.1	4.1

<sup>a</sup> Study conducted in Poland.

<sup>b</sup> Number of subjects reporting Yes for at least 1 day or No for all days.

<sup>c</sup> Diameters were measured in caliper units of whole numbers from 1 to 14 or 14+. One caliper unit = 0.5 cm. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling were then characterized as Mild (0.5-2.0 cm), Moderate (2.5-7.0 cm), or Severe (>7.0 cm).

lowing each dose of Prevnar 13 administered to pneumococcal-vaccine naive children 7 months through 5 years of age are shown in Tables 5 and 6.

[See table 5 above]

[See table 6 at top of next page]

A U.S. study evaluated the use of Prevnar 13 in children previously immunized with Prevnar. In this open label trial,

284 healthy children 15 through 59 months of age previously vaccinated with at least 3 doses of Prevnar, received 1 or 2 doses of Prevnar 13. Children 15 months through 23 months of age (group 1) received 2 doses, and children 24 months through 59 months of age (group 2) received one dose. Most subjects were White (75.0%), 15.8% were Black or African-American, and 1.6% were Asian; 86.6% of

**Table 6: Percentage of Subjects 7 Months Through 5 Years of Age Reporting Solicited Systemic Adverse Reactions Within 4 Days After Each Catch-Up Prevnar 13 Vaccination<sup>a</sup>**

Systemic Reaction	7 through 11 months			12 through 23 months		24 months through 5 years
	Dose 1 N <sup>b</sup> =86-87 %	Dose 2 N <sup>b</sup> =86-87 %	Dose 3 N <sup>b</sup> =78-81 %	Dose 1 N <sup>b</sup> =108 %	Dose 2 N <sup>b</sup> =98-100 %	Dose 1 N <sup>b</sup> =147-148 %
Fever <sup>c</sup>						
Mild	3.4	8.1	5.1	3.7	5.1	0.7
Moderate	1.2	2.3	1.3	0.9	0.0	0.7
Severe	0.0	0.0	0.0	0.0	0.0	0.0
Decreased appetite	19.5	17.2	17.5	22.2	25.5	16.3
Irritability	24.1	34.5	24.7	30.6	34.0	14.3
Increased sleep	9.2	9.3	2.6	13.0	10.1	11.6
Decreased sleep	24.1	18.4	15.0	19.4	20.4	6.8

<sup>a</sup> Study conducted in Poland.  
<sup>b</sup> Number of subjects reporting Yes for at least 1 day or No for all days.  
<sup>c</sup> Fever gradings: Mild ( $\geq 38^{\circ}\text{C}$  but  $\leq 39^{\circ}\text{C}$ ), Moderate ( $>39^{\circ}\text{C}$  but  $\leq 40^{\circ}\text{C}$ ), and Severe ( $> 40^{\circ}\text{C}$ ). No other systemic event other than fever was graded.

**Table 7: Percentage of Subjects 15 Months Through 59 Months of Age, Previously Vaccinated with 3 or 4 Prior Infant Doses of Prevnar, Reporting Solicited Local Reactions Within 7 Days After One Supplemental Prevnar 13 Vaccination**

Graded Local Reaction	15 months through 23 months <sup>a</sup>		24 months through 59 months <sup>b</sup>
	1 dose Prevnar 13 3 prior Prevnar doses N <sup>c</sup> =28-32 %	1 dose Prevnar 13 4 prior Prevnar doses N <sup>c</sup> =62-76 %	1 dose Prevnar 13 3 or 4 prior Prevnar doses N <sup>c</sup> =138-155 %
Redness <sup>d</sup>			
Any	46.9	36.6	34.9
Mild	31.0	31.4	31.5
Moderate	22.6	7.9	9.9
Severe	0.0	0.0	0.0
Swelling <sup>d</sup>			
Any	35.5	21.2	22.2
Mild	26.7	18.8	20.3
Moderate	13.8	7.7	5.7
Severe	0.0	0.0	0.0
Tenderness			
Any	53.1	50.0	61.9
Interferes with limb movement	10.3	6.3	10.6

<sup>a</sup> Dose 2 data not shown.  
<sup>b</sup> The data for this age group are only represented as a single result as 95% of children received 4 doses of Prevnar prior to enrollment.  
<sup>c</sup> Number of subjects reporting Yes for at least 1 day or No for all days.  
<sup>d</sup> Diameters were measured in caliper units of whole numbers from 1 to 14 or 14+. One caliper unit = 0.5 cm. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling were then characterized as Mild (0.5-2.0 cm), Moderate (2.5-7.0 cm), or Severe (>7.0 cm).

subjects were non-Hispanic and non-Latino and 13.4% were Hispanic or Latino. Overall, 54.0% of subjects were male infants. The incidence and severity of solicited adverse reactions that occurred within 7 days following one dose of Prevnar 13 administered to children 15 months through 59 months of age are shown in Tables 7 and 8. [See table 8 at top of next page]

**6.2 Clinical Trials Experience With Prevnar<sup>®</sup>**  
 The safety experience with Prevnar is relevant to Prevnar 13 because the two vaccines share common components. Generally, the adverse reactions reported in clinical trials with Prevnar 13 were also reported in clinical trials with Prevnar.

Overall, the safety of Prevnar was evaluated in a total of five clinical studies in the U.S. in which 18,168 infants and children received a total of 58,699 doses of vaccine at 2, 4, 6, and 12-15 months of age. Adverse events reported in clinical trials with Prevnar include: Bronchiolitis, UTI, acute gastroenteritis, asthma, aspiration, breath holding, influenza, inguinal hernia repair, viral syndrome, URI, croup, thrush, wheezing, choking, conjunctivitis, pharyngitis, colic, colitis, congestive heart failure, roseola, sepsis.

**6.3 Post-marketing Experience With Prevnar**  
 The following adverse reactions have been reported through passive surveillance since market introduction of Prevnar and therefore, are considered adverse reactions for Prevnar

13 as well. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate its frequency or establish a causal relationship to the vaccine.

**Administrative site conditions:** Injection-site dermatitis, injection-site pruritus, injection-site urticaria

**Blood and lymphatic system disorders:** Lymphadenopathy localized to the region of the injection site

**Immune system disorders:** Anaphylactic/anaphylactoid reaction including shock

**Skin and subcutaneous tissue disorders:** Angioneurotic edema, erythema multiforme

**Respiratory:** Apnea

The safety of Prevnar given concomitantly with other vaccines as part of routine care was assessed in a three-year observational study performed at Northern California Kaiser Permanente in which 65,927 children received three doses of Prevnar in the first year of life. Primary safety outcomes analyses included an evaluation of pre-defined adverse events occurring in temporal relationship to immunization. Rates of adverse events occurring within various time periods post-vaccination (e.g., 0-2, 0-7, 0-14, and 0-30 days) were compared to the rates of those events occurring within a control time window (i.e., 31-60 days). Secondary safety outcomes analyses included comparisons to a historical control population of infants (1995-1996, N=40,223) prior to the introduction of Prevnar. In addition, the study included extended follow-up of subjects originally enrolled in the NCKP efficacy trial (N=37,866).

The primary safety outcomes analyses did not demonstrate a consistently elevated risk of healthcare utilization for croup, gastroenteritis, allergic reactions, seizures, wheezing diagnoses, or breath-holding across doses, healthcare settings, or multiple time windows. As in prelicensure trials, fever was associated with Prevnar administration. In analyses of secondary safety outcomes, the adjusted relative risk of hospitalization for reactive airways disease was 1.23 (95% CI: 1.11, 1.35). Potential confounders, such as differences in concomitantly administered vaccines, yearly variation in respiratory infections, or secular trends in reactive airways disease incidence, could not be controlled. Extended follow-up of subjects originally enrolled in the NCKP efficacy trial revealed no increased risk of reactive airways disease among Prevnar recipients. In general, the study results support the previously described safety profile of Prevnar.

**7 DRUG INTERACTIONS**

**7.1 Concomitant Immunizations**

In clinical trials, Prevnar 13 was administered concomitantly with the following U.S. licensed vaccines: Pediarix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined] (DTaP-HBV-IPV) and ActHIB [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] (PRP-T) for the first three doses and with PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] (PRP-OMP), M-M-R II [Measles, Mumps, Rubella Virus Vaccine Live] (MMR) and Varivax [Varicella Virus Vaccine Live], or ProQuad [Measles, Mumps, Rubella and Varicella Virus Vaccine Live] (MMRV) and VAQTA [Hepatitis A vaccine, Inactivated] (HepA) for dose 4 [see Clinical Studies (14.2)].

When Prevnar 13 is administered at the same time as another injectable vaccine(s), the vaccines should always be administered with different syringes and given at different injection sites.

Do not mix Prevnar 13 with other vaccines/products in the same syringe.

**7.2 Immunosuppressive Therapies**

Children with impaired immune responsiveness due to the use of immunosuppressive therapy (including irradiation, corticosteroids, antimetabolites, alkylating agents, and cytotoxic agents) may not respond optimally to active immunization.

**8 USE IN SPECIFIC POPULATIONS**

**8.1 Pregnancy**

**Pregnancy Category C**

Animal reproduction studies have not been conducted with Prevnar 13. It is also not known whether Prevnar 13 can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity.

**8.4 Pediatric Use**

Safety and effectiveness of Prevnar 13 in children below the age of 6 weeks or on or after the 6<sup>th</sup> birthday have not been established. Prevnar 13 is not approved for use in children in these age groups [see Dosage and Administration (2)]. Immune responses elicited by Prevnar 13 among infants born prematurely have not been specifically studied.

**8.5 Geriatric Use**

The safety and effectiveness of Prevnar 13 in geriatric populations have not been established.

**IMPORTANT NOTICE:** Updated drug information is sent bi-monthly via the PDR<sup>®</sup> Update Insert. For monthly email updates, register at PDR.net.

Prevnar 13 pneumococcal population  
 10 OV  
 Overdose as a pre-f  
 overdose -  
 ministe  
 In genera  
 sistent w  
 given in t  
 11 DE  
 Prevnar 13 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined) (DTaP-HBV-IPV) and ActHIB [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] (PRP-T) for the first three doses and with PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] (PRP-OMP), M-M-R II [Measles, Mumps, Rubella Virus Vaccine Live] (MMR) and Varivax [Varicella Virus Vaccine Live], or ProQuad [Measles, Mumps, Rubella and Varicella Virus Vaccine Live] (MMRV) and VAQTA [Hepatitis A vaccine, Inactivated] (HepA) for dose 4 [see Clinical Studies (14.2)].  
 12 C  
 A serum  
 tion of 0.  
 as a sing  
 timate t  
 say used  
 volving  
 C-polysa  
 non-spe  
 erence v  
 three pl  
 Prevnar  
 pneumo  
 concentr  
 not be u  
 usual basi  
 measur  
 evaluat  
 12.1  
 B-cells  
 tion vi  
 Prevnar  
 carrier  
 Protein  
 maturat  
 memori  
 and elig  
 young  
 13  
 13.1  
 tility  
 Prevnar  
 mutage  
 14  
 14.1  
 Invasiv  
 Prevnar  
 domize  
 tion at  
 from 0  
 37,816  
 a contr  
 conjug  
 age. In  
 diseas  
 period

Pprevnar 13 is not to be used as a substitute for 23-valent pneumococcal polysaccharide vaccine (PPV23) in geriatric populations.

#### 10 OVERDOSAGE

Overdose with Pprevnar 13 is unlikely due to its presentation as a pre-filled syringe. However, there have been reports of overdose with Pprevnar 13 defined as subsequent doses administered closer than recommended to the previous dose. In general, adverse events reported with overdose are consistent with those which have been reported with doses given in the recommended schedules of Pprevnar 13.

#### 11 DESCRIPTION

Pprevnar 13, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM<sub>197</sub> Protein) is a sterile suspension of saccharides of the capsular antigens of *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM<sub>197</sub> protein. Each serotype is grown in soy peptone broth. The individual polysaccharides are purified through centrifugation, precipitation, ultrafiltration, and column chromatography. The polysaccharides are chemically activated to make saccharides, which are directly conjugated by reductive amination to the protein carrier CRM<sub>197</sub>, to form the glycoconjugate. CRM<sub>197</sub> is a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197) grown in a casamino acids and yeast extract-based medium. CRM<sub>197</sub> is purified through ultrafiltration, ammonium sulfate precipitation, and ion-exchange chromatography. The individual glycoconjugates are purified by ultrafiltration and column chromatography and analyzed for saccharide to protein ratios, molecular size, free saccharide, and free protein.

The individual glycoconjugates are compounded to formulate Pprevnar 13. Potency of the formulated vaccine is determined by quantification of each of the saccharide antigens and by the saccharide to protein ratios in the individual glycoconjugates. Each 0.5 mL dose of the vaccine is formulated to contain approximately 2.2 µg of each of *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides, 4.4 µg of 6B saccharides, 34 µg CRM<sub>197</sub> carrier protein, 100 µg polysorbate 80, 295 µg succinate buffer and 125 µg aluminum as aluminum phosphate adjuvant.

The tip cap and rubber plunger of the pre-filled syringe do not contain latex.

#### 12 CLINICAL PHARMACOLOGY

A serum anti-capsular polysaccharide antibody concentration of 0.35 µg/mL measured one month after the third dose as a single antibody reference concentration was used to estimate the effectiveness of Pprevnar 13 against IPD. The assay used for this determination is a standardized ELISA involving pre-absorption of the test sera with pneumococcal C-polysaccharide and serotype 22F polysaccharide to reduce non-specific background reactivity. The single antibody reference value was based on pooled efficacy estimates from three placebo-controlled IPD efficacy trials with either Pprevnar or the investigational 9-valent CRM<sub>197</sub> conjugate pneumococcal polysaccharide vaccine. This reference concentration is only applicable on a population basis and cannot be used to predict protection against IPD on an individual basis. Functional antibodies elicited by the vaccine (as measured by opsonophagocytic assay [OPA]) were also evaluated.

#### 12.1 Mechanism of Action

B-cells produce antibodies in response to antigenic stimulation via T-dependent and T-independent mechanisms. Pprevnar 13, comprised of polysaccharides conjugated to a carrier protein, elicits a T-cell dependent immune response. Protein carrier-specific T-cells provide the signals needed for maturation of the B-cell response and generation of B-cell memory. This type of response induces immune memory and elicits booster responses on re-exposure in infants and young children to pneumococcal polysaccharides.

#### 13 NONCLINICAL TOXICOLOGY

##### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Pprevnar 13 has not been evaluated for any carcinogenic or mutagenic potential, or impairment of fertility.

#### 14 CLINICAL STUDIES

##### 14.1 Pprevnar Efficacy Data Invasive Pneumococcal Disease (IPD)

Pprevnar was licensed in the U.S. in 2000, following a randomized, double-blind clinical trial in a multiethnic population at Northern California Kaiser Permanente (NCKP) from October 1995 through August 20, 1998, in which 37,816 infants were randomized to receive either Pprevnar or a control vaccine (an investigational meningococcal group C conjugate vaccine [MnCC]) at 2, 4, 6, and 12-15 months of age. In this study, the efficacy of Pprevnar against invasive disease due to *S. pneumoniae* in cases accrued during this period was 100% in both the per-protocol and intent-to-treat

**Table 8: Percentage of U.S. Subjects 15 Months Through 59 Months of Age, Previously Vaccinated with 3 or 4 Prior Infant Pprevnar Doses, Reporting Solicited Systemic Adverse Reactions Within 7 Days After One Supplemental Pprevnar 13 Vaccination**

Systemic Reaction	15 months through 23 months <sup>a</sup>		24 months through 59 months <sup>b</sup>
	1 dose Pprevnar 13 3 prior Pprevnar doses N <sup>c</sup> =28-33 %	1 dose Pprevnar 13 4 prior Pprevnar doses N <sup>c</sup> =62-75 %	1 dose Pprevnar 13 3 or 4 prior Pprevnar doses N <sup>c</sup> =138-151 %
Fever <sup>d</sup>			
Mild	10.7	18.8	5.1
Moderate	7.1	3.2	0.7
Severe	0.0	0.0	0.7
Decreased appetite	56.7	36.2	24.8
Irritability	66.7	57.3	39.7
Increased sleep	30.0	33.8	15.9
Decreased sleep	22.6	22.7	14.0

<sup>a</sup> Dose 2 data not shown.

<sup>b</sup> The data for this age group are only represented as a single result as 95% of children received 4 doses of Pprevnar prior to enrollment.

<sup>c</sup> Number of subjects reporting Yes for at least 1 day or No for all days.

<sup>d</sup> Fever gradings: Mild ( $\geq 38^{\circ}\text{C}$  but  $\leq 39^{\circ}\text{C}$ ), Moderate ( $> 39^{\circ}\text{C}$  but  $\leq 40^{\circ}\text{C}$ ), and Severe ( $> 40^{\circ}\text{C}$ ). No other systemic event other than fever was graded.

**Table 9: Percentage of Subjects With Anti-capsular Antibody Concentration  $\geq 0.35$  µg/mL One Month After Dose 3, U.S. Pivotal Non-inferiority Study<sup>a†</sup>**

Serotype	Pprevnar 13 N=249-252 (95% CI)	Pprevnar N=250-252 (95% CI)	Difference in % responders (95% CI)
<b>Pprevnar Serotypes</b>			
4	94.4 (90.9, 96.9)	98.0 (95.4, 99.4)	-3.6 (-7.3, -0.1)
6B	87.3 (82.5, 91.1)	92.8 (88.9, 95.7)	-5.5 (-10.9, -0.1)
9V	90.5 (86.2, 93.8)	98.4 (96.0, 99.6)	-7.9 (-12.4, -4.0)
14	97.6 (94.9, 99.1)	97.2 (94.4, 98.9)	0.4 (-2.7, 3.5)
18C	96.8 (93.8, 98.6)	98.4 (96.0, 99.6)	-1.6 (-4.7, 1.2)
19F	98.0 (95.4, 99.4)	97.6 (99.4, 99.1)	0.4 (-2.4, 3.4)
23F	90.5 (86.2, 93.8)	94.0 (90.4, 96.6)	-3.6 (-8.5, 1.2)
<b>Additional Serotypes<sup>††</sup></b>			
1	95.6 (92.3, 97.8)	††	2.8 (-1.3, 7.2)
3	63.5 (57.1, 69.4)	††	-29.3 (-36.2, -22.4)
5	89.7 (85.2, 93.1)	††	-3.1 (-8.3, 1.9)
6A	96.0 (92.8, 98.1)	††	3.2 (-0.8, 7.6)
7F	98.4 (96.0, 99.6)	††	5.6 (1.9, 9.7)
19A	98.4 (96.0, 99.6)	††	5.6 (1.9, 9.7)

<sup>a</sup> Non-inferiority was met when the lower bound of the 95% CI for the difference between groups (Pprevnar 13 minus Pprevnar) was greater than -10%.

<sup>†</sup> Antibody measured by a standardized ELISA involving pre-absorption of the test sera with pneumococcal C-polysaccharide and serotype 22F polysaccharide to reduce non-specific background reactivity.

<sup>††</sup> Comparison for the 6 additional serotypes was to the lowest responder of the 7 common serotypes in Pprevnar recipients, which for this analysis was serotype 6B (92.8%; 95% CI: 88.9, 95.7).

analyses (95% CI: 75.4%-100% and 81.7%-100%, respectively). Data accumulated through an extended follow-up period to April 20, 1999, resulted in similar efficacy estimates of 97.4% in the per-protocol analysis and 93.9% in the intent-to-treat analysis (95% CI: 82.7%-99.9% and 79.6%-98.5%, respectively).

##### Acute Otitis Media (AOM)

The efficacy of Pprevnar against otitis media was assessed in two clinical trials: a trial in Finnish infants at the National Public Health Institute and the pivotal efficacy trial in U.S. infants at Northern California Kaiser Permanente (NCKP). The Finnish Otitis Media (FinOM) trial was a randomized, double-blind trial in which 1,662 infants were equally randomized to receive either Pprevnar or a control vaccine

Recombinax HB (Hepatitis B vaccine (Recombinant) [Hep B]) at 2, 4, 6, and 12-15 months of age. In this study, conducted between December 1995 and March 1999, parents of study participants were asked to bring their children to the study clinics if the child had respiratory infections or symptoms suggesting acute otitis media (AOM). If AOM was diagnosed, tympanocentesis was performed, and the middle-ear fluid was cultured. If *S. pneumoniae* was isolated, serotyping was performed; the primary endpoint was efficacy against AOM episodes caused by vaccine serotypes in the per-protocol population. In the NCKP trial, the efficacy of Pprevnar against otitis media was assessed from the beginning of the trial in October 1995 through April 1998. The otitis media analysis included 34,146 infants randomized to

**Table 10: Pneumococcal OPA Geometric Mean Titers One Month After the Third Dose-Evaluable Immunogenicity Population, U.S. Pivotal Non-inferiority Study\***

Serotype	Prevnar 13 N=91-94 (95% CI)	Prevnar N=89-94 (95% CI)
<b>Prevnar Serotypes</b>		
4	359 (276, 468)	536 (421, 681)
6B	1055 (817, 1361)	1514 (1207, 1899)
9V	4035 (2933, 5553)	3259 (2288, 4641)
14	1240 (935, 1646)	1481 (1133, 1934)
18C	276 (210, 361)	376 (292, 484)
19F	54 (40, 74)	45 (34, 60)
23F	791 (605, 1034)	924 (709, 1204)
<b>Additional Serotypes</b>		
1	52 (39, 69)	4 (4, 5)
3	121 (92, 158)	7 (5, 9)
5	91 (67, 123)	4 (4, 4)
6A	980 (783, 1226)	100 (66, 152)
7F	9494 (7339, 12281)	128 (80, 206)
19A	152 (105, 220)	7 (5, 9)

\* The OPA (opsonophagocytic activity) assay measures the ability of immune sera, in conjunction with complement, to mediate the uptake and killing of *S. pneumoniae* by phagocytic cells.

**Table 11: Pneumococcal IgG GMCs (µg/mL) One Month After Dose 4, U.S. Pivotal Non-inferiority Study\*†**

Serotype	Prevnar 13 N=232-236 (95% CI)	Prevnar N=222-223 (95% CI)	GMC Ratio (95% CI)
<b>Prevnar Serotypes</b>			
4	3.73 (3.28, 4.24)	5.49 (4.91, 6.13)	0.68 (0.57, 0.80)
6B	11.53 (9.99, 13.30)	15.63 (13.80, 17.69)	0.74 (0.61, 0.89)
9V	2.62 (2.34, 2.94)	3.63 (3.25, 4.05)	0.72 (0.62, 0.85)
14	9.11 (7.95, 10.45)	12.72 (11.22, 14.41)	0.72 (0.60, 0.86)
18C	3.20 (2.82, 3.64)	4.70 (4.18, 5.28)	0.68 (0.57, 0.81)
19F	6.60 (5.85, 7.44)	5.60 (4.87, 6.43)	1.18 (0.98, 1.41)
23F	5.07 (4.41, 5.83)	7.84 (6.91, 8.90)	0.65 (0.54, 0.78)
<b>Additional Serotypes††</b>			
1	5.06 (4.43, 5.80)	††	1.40 (1.17, 1.66)
3	0.94 (0.83, 1.05)	††	0.26 (0.22, 0.30)
5	3.72 (3.31, 4.18)	††	1.03 (0.87, 1.20)
6A	8.20 (7.30, 9.20)	††	2.26 (1.93, 2.65)
7F	5.67 (5.01, 6.42)	††	1.56 (1.32, 1.85)
19A	8.55 (7.64, 9.56)	††	2.36 (2.01, 2.76)

\* Non-inferiority was declared if the lower limit of the 2-sided 95% CI for Geometric Mean Ratio (Prevnar 13:Prevnar) was greater than 0.5.

† Antibody measured by a standardized ELISA involving pre-absorption of the test sera with pneumococcal C-polysaccharide and serotype 22F polysaccharide to reduce non-specific background reactivity.

†† Comparison for the 6 additional serotypes was to the lowest responder of the 7 common serotypes in Prevnar recipients, which for this analysis was serotype 9V (3.63; 95% CI 3.25, 4.05).

receive either Prevnar (N=17,070), or the control vaccine (N=17,076), at 2, 4, 6, and 12-15 months of age. In this trial, no routine tympanocentesis was performed, and no standard definition of otitis media was used by study physicians. The primary otitis media endpoint was efficacy against all otitis media episodes in the per-protocol population.

The vaccine efficacy against AOM episodes due to vaccine serotypes assessed in the Finnish trial, was 57% (95% CI: 44%-67%) in the per-protocol population and 54% (95% CI: 41%-64%) in the intent-to-treat population. The vaccine ef-

ficacy against AOM episodes due to vaccine-related serotypes (6A, 9N, 18B, 19A, 23A), also assessed in the Finnish trial, was 51% (95% CI: 27, 67) in the per-protocol population and 44% (95% CI: 20, 62) in the intent-to-treat population. There was a nonsignificant increase in AOM episodes caused by serotypes unrelated to the vaccine in the per-protocol population, compared to children who received the control vaccine, suggesting that children who received Prevnar appeared to be at increased risk of otitis media due to pneumococcal serotypes not represented in the vaccine.

However, vaccination with Prevnar reduced pneumococcal otitis media episodes overall. In the NCKP trial, in which the endpoint was all otitis media episodes regardless of etiology, vaccine efficacy was 7% (95% CI: 4%-10%) and 6% (95% CI: 4%-9%), respectively, in the per-protocol and intent-to-treat analyses. Several other otitis media endpoints were also assessed in the two trials.

Recurrent AOM, defined as 3 episodes in 6 months or 4 episodes in 12 months, was reduced by 9% in both the per-protocol and intent-to-treat populations (95% CI: 3%-15% in per-protocol and 95% CI: 4%-14% in intent-to-treat) in the NCKP trial; a similar trend was observed in the Finnish trial. The NCKP trial also demonstrated a 20% reduction (95% CI: 2, 35) in the placement of tympanostomy tubes in the per-protocol population and a 21% reduction (95% CI: 4, 34) in the intent-to-treat population. Data from the NCKP trial accumulated through an extended follow-up period to April 20, 1999, in which a total of 37,866 children were included (18,925 in Prevnar group and 18,941 in MnCC control group), resulted in similar otitis media efficacy estimates for all endpoints.

#### 14.2 Evaluation of Prevnar 13 Effectiveness

Prevnar 13 effectiveness against invasive pneumococcal disease was inferred from comparative studies to a U.S. licensed 7-valent pneumococcal conjugate vaccine, Prevnar, in which Prevnar 13 elicited immune responses as measured by antipolysaccharide binding and functional OPA antibodies. These studies were designed to evaluate immunologic non-inferiority of Prevnar 13 to Prevnar.

Clinical trials have been conducted in the U.S. using a 2, 4, 6, and 12 to 15 month schedule.

The pivotal U.S. non-inferiority study was a randomized, double-blind, active-controlled trial in which 2 month-old infants were randomly assigned to receive either Prevnar 13 or Prevnar in a 1:1 ratio. The 2 vaccine groups were well balanced with respect to race, ethnicity, and age and weight at enrollment. Most subjects were White (69.1%), 19.6% were Black or African-American, and 2.4% were Asian; 82.1% of subjects were non-Hispanic and non-Latino and 17.3% were Hispanic or Latino. Overall, 54.0% of subjects were male infants.

In the pivotal U.S. non-inferiority study, immune responses were compared in subjects receiving either Prevnar 13 or Prevnar using a set of non-inferiority criteria. Co-primary endpoints included the percentage of subjects with serum pneumococcal anti-capsular polysaccharide IgG  $\geq 0.35$  µg/mL measured one month after the third dose and serum pneumococcal anti-capsular polysaccharide IgG geometric mean concentrations (GMCs) one month after the fourth dose. The assay used for this determination was a standardized ELISA involving pre-absorption of the test sera with pneumococcal C-polysaccharide and serotype 22F polysaccharide to reduce non-specific background reactivity. Responses to the 7 common serotypes in Prevnar 13 and Prevnar recipients were compared directly. Responses to the 6 additional serotypes in Prevnar 13 recipients were each compared to the lowest response observed among the Prevnar serotypes in Prevnar recipients.

#### Pneumococcal Immune Responses Following Three Doses

In the pivotal U.S. non-inferiority study, the non-inferiority criterion for the proportion of subjects with pneumococcal anti-capsular polysaccharide IgG antibody concentrations  $\geq 0.35$  µg/mL one month after the third dose was met for 10 of the 13 serotypes. The exceptions were serotypes 6B, 9V, and 3. Although the response to serotypes 6B and 9V did not meet the pre-specified non-inferiority criterion, the differences were marginal. The clinical relevance of these differences, if any, is unknown.

The percentage of infants achieving pneumococcal anti-capsular polysaccharide IgG antibody concentrations  $\geq 0.35$  µg/mL one month after the third dose is shown below (Table 9).

[See table 9 on previous page]

Functional OPA antibody responses were elicited for all 13 serotypes, as shown in Table 10.

[See table 10 above]

#### Pneumococcal Immune Responses Following Four Doses

In the pivotal U.S. non-inferiority study, post-dose 4 antibody concentrations were higher for all 13 serotypes than those achieved after the third dose. The non-inferiority criterion for pneumococcal anti-capsular polysaccharide GMCs after 4 doses was met for 12 of the 13 pneumococcal serotypes. The non-inferiority criterion was not met for the response to serotype 3 (Table 11).

[See table 11 at left]

Following the 4th dose, the functional OPA response for each serotype was quantitatively greater than the response following the 3rd dose (see Table 12).

[See table 12 at top of next page]

**IMPORTANT NOTICE:** Updated drug information is sent bi-monthly via the PDR® Update Insert. For monthly email updates, register at PDR.net.

Table 12: Pneumococcal OPA Geometric Mean Titers One Month After the Fourth Dose-Evaluable Toddler Immunogenicity Population, U.S. Pivotal Non-inferiority Study\*

Serotype	Pneumococcal OPA Geometric Mean Titers	
	Prevnar 13 N=88-92 (95% CI)	Prenvar N=92-96 (95% CI)
<b>Pneumococcal Serotypes</b>		
4	1180 (847, 1643)	1492 (1114, 1999)
6B	3100 (2337, 4111)	4066 (3243, 5098)
9V	11856 (8810, 15955)	18032 (14125, 23021)
14	2002 (1453, 2760)	2366 (1871, 2992)
18C	993 (754, 1308)	1722 (1327, 2236)
19F	200 (144, 276)	167 (121, 230)
23F	2723 (1961, 3782)	4982 (3866, 6387)
<b>Additional Serotypes</b>		
1	164 (114, 237)	5 (4, 6)
3	380 (300, 482)	12 (9, 16)
5	300 (229, 393)	5 (4, 6)
6A	2242 (1707, 2945)	539 (375, 774)
7F	11629 (9054, 14938)	268 (165, 436)
19A	1024 (774, 1355)	29 (19, 44)

\* The OPA (opsonophagocytic activity) assay measures the ability of immune sera, in conjunction with complement, to mediate the uptake and killing of *S. pneumoniae* by phagocytic cells.

Table 13: Pneumococcal Anti-capsular Polysaccharide IgG Antibody Geometric Mean Concentrations (µg/mL) One Month After the Final Prevnar 13 Catch-Up Dose in Pneumococcal Vaccine Naïve Children 7 Months through 5 Years of Age by Age Group, Poland Catch-Up Study

Serotype	Pneumococcal Anti-capsular Polysaccharide IgG Antibody Geometric Mean Concentrations (µg/mL)		
	3 doses Prevnar 13 7 through 11 months N=83-84 (95% CI)	2 doses Prevnar 13 12 through 23 months N=104-110 (95% CI)	1 dose Prevnar 13 24 months through 5 years N=135-152 (95% CI)
1	2.88 (2.44, 3.39)	2.74 (2.37, 3.16)	1.78 (1.52, 2.08)
3	1.94 (1.68, 2.24)	1.86 (1.60, 2.15)	1.42 (1.23, 1.64)
4	3.63 (3.11, 4.23)	4.28 (3.78, 4.86)	3.37 (2.95, 3.85)
5	2.85 (2.34, 3.46)	2.16 (1.89, 2.47)	2.33 (2.05, 2.64)
6A	3.72 (3.12, 4.45)	2.62 (2.25, 3.06)	2.96 (2.52, 3.47)
6B	4.77 (3.90, 5.84)	3.38 (2.81, 4.06)	3.41 (2.80, 4.16)
7F	5.30 (4.54, 6.18)	5.99 (5.40, 6.65)	4.92 (4.26, 5.68)
9V	2.56 (2.21, 2.96)	3.08 (2.69, 3.53)	2.67 (2.32, 3.07)
14	8.04 (6.95, 9.30)	6.45 (5.48, 7.59)	2.24 (1.71, 2.93)
18C	2.77 (2.39, 3.23)	3.71 (3.29, 7.19)	2.56 (2.17, 3.03)
19A	4.77 (4.28, 5.33)	4.94 (4.31, 5.65)	6.03 (5.22, 6.97)
19F	2.88 (2.35, 3.54)	3.07 (2.68, 3.51)	2.53 (2.14, 2.99)
23F	2.16 (1.82, 2.55)	1.98 (1.64, 2.39)	1.55 (1.31, 1.85)

**Simultaneous Administration With Other Vaccines**

The concomitant administration of routine U.S. infant vaccines [see *Drug Interactions (7.1)*] with Prevnar 13 was evaluated in two studies: the U.S. pivotal non-inferiority study [see *Clinical Studies (14.2)*, *Pneumococcal Immune Responses Following Three Doses*] and the U.S. lot consistency study. In the lot consistency study, subjects were randomly assigned to receive one of 3 lots of Prevnar 13 or Prevnar in a 2:2:1 ratio. The total number of infants vaccinated was 663 (U.S. non-inferiority study) and 1699 (U.S. lot consistency study). Immune responses to concomitant vaccine antigens were compared in infants receiving Prevnar and Prevnar 13. Responses to diphtheria toxoid, tetanus toxoid, pertussis, polio types 1, 2, and 3, hepatitis B, PRP-T, PRP-OMP, measles, and varicella antigens in Prevnar 13 recipients were similar to those in Prevnar recipients. Based on limited data, responses to mumps and rubella antigens in Prevnar 13 recipients were similar to those in Prevnar recipients.

**Previously Unvaccinated Older Infants and Children**

In an open-label descriptive study of Prevnar 13 in Poland, children 7 through 11 months of age, 12 through 23 months of age and 24 months through 5 years of age (prior to the 6<sup>th</sup> birthday) who were naïve to pneumococcal conjugate vaccine, were given 3, 2 or 1 dose of Prevnar 13 respectively, according to the age-appropriate schedules in Table 1. Serum IgG concentrations were measured one month after the final dose in each age group and the data are shown in Table 13. [See table 13 above]

**Children Previously Vaccinated with Prevnar**

In an open-label descriptive study in the U.S., children previously vaccinated with 3 or 4 doses of Prevnar, received 2 doses of Prevnar 13 (children 15 through 23 months of age) or 1 dose of Prevnar 13 (children 24 months through 59 months of age). The data following one dose of Prevnar 13 in children 24 months through 59 months of age are shown in Table 14.

Table 14: Pneumococcal Anti-capsular Polysaccharide IgG Antibody Geometric Mean Concentrations (µg/mL) One Month After One Prevnar 13 Catch-Up Dose in Children 24 through 59 Months of Age With 3 or 4 Prior Doses of Prevnar, U.S. Catch-Up Study

Serotype	Pneumococcal Anti-capsular Polysaccharide IgG Antibody Geometric Mean Concentrations (µg/mL)	
	1 dose Prevnar 13 24 months through 59 months N=173-175 (95% CI)	3 or 4 prior doses of Prevnar
1	2.43 (2.15, 2.75)	
3	1.38 (1.17, 1.61)	
5	2.13 (1.89, 2.41)	
6A	12.96 (11.04, 15.21)	
7F	4.22 (3.74, 4.77)	
19A	14.18 (12.37, 16.25)	

**16 HOW SUPPLIED/STORAGE AND HANDLING**

Pre-filled Syringe, 1 Dose (10 per package) - NDC 0005-1971-02.

Store refrigerated at +2°C to +8°C (36°F to 46°F). The tip cap and rubber plunger of the pre-filled syringe do not contain latex.

Do not freeze. Discard if the vaccine has been frozen.

**17 PATIENT COUNSELING INFORMATION****17.1 Potential Benefits and Risks**

Prior to administration of this vaccine, the healthcare professional should inform the parent, guardian, or other responsible adult of the potential benefits and risks to the patient [see *Warnings and Precautions (5)* and *Adverse Reactions (6)*], and the importance of completing the immunization series unless contraindicated.

**17.2 Adverse Reactions**

Instruct parents, guardians, or other responsible adults to report any suspected adverse reactions to their healthcare professional.

**Wyeth®**

Wyeth Pharmaceuticals Inc.

Philadelphia, PA 19101

U.S. Govt. License No. 3

W10543C003

ET01

Rev 04/10

CPT Code 90670

United States Patent Number: 5,614,382.

**PRISTIQ®**

[*pris-TEEK*]

(desvenlafaxine)

Extended-Release Tablets, Oral

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ. PRISTIQ® (desvenlafaxine) Extended-Release Tablets, oral Initial U.S. Approval: 2008

**WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS**

See full prescribing information for complete boxed warning.

Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders. PRISTIQ is not approved for use in pediatric patients (5.1).

**RECENT MAJOR CHANGES**

Dosage and Administration, Switching Patients From Other Antidepressants to PRISTIQ (2.5) 11/2009

**INDICATIONS AND USAGE**

PRISTIQ, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD) (1).

**—DOSAGE AND ADMINISTRATION—**

- Recommended dose: 50 mg once daily with or without food (2.1).
- There was no evidence that doses greater than 50 mg/day confer any additional benefit (2.1).
- When discontinuing treatment, gradual dose reduction is recommended whenever possible (2.1 and 5.9).
- Tablets should be taken whole; do not divide, crush, chew, or dissolve (2.1).
- Renal Impairment: The recommended dose in patients with moderate renal impairment is 50 mg/day. The recommended dose in patients with severe renal impairment